Prostate-specific antigen: An overlooked candidate for the targeted treatment and selective imaging of prostate cancer

Biological Chemistry

Volumn 391, Issue 4, 2010, Pages 333-343

  Lebeau, Aaron M ^a,c   Kostova, Maya ^b   Craik, Charles S ^c   Denmeade, Samuel R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human kallikrein related peptidase 3; Inhibition; Prostate cancer; Prostate specific antigen; Serine protease; Small molecule

Indexed keywords

ALDEHYDE DERIVATIVE; BORONIC ACID DERIVATIVE; CHYMOTRYPSIN; ENZYME INHIBITOR; KALLIKREIN; KALLIKREIN 3; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; ENZYME INHIBITOR INTERACTION; ENZYME SPECIFICITY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MALE; MOLECULAR IMAGING; MOLECULAR SEQUENCE DATA; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUBSTRATE SPECIFICITY;

EID: 77951489238     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2010.044     Document Type: Conference Paper

References (60)

1. Adlington, R.M., Baldwin, J.E., Chen, B., Cooper, S.L., McCoull, W.M., Pritchard, G.E., Howe, T.J., Becker, G.W., Hermann, R.B., McNulty, A.M., et al. (1997). Design and synthesis of novel monocyclic b-lactam inhibitors of prostate-specific antigen. Bioorg. Med. Chem. Lett. 7, 1689-1694.
2. Adlington, R.M., Baldwin, J.E., Becker, G.W., Chen, B., Cheng, L., Cooper, S.L., Hermann, R.B., Howe, T.J., McCoull, W., Mc-Nulty, A.M., et al. (2001). Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigen. J. Med. Chem. 44, 1491-1508.
3. Bone, R., Shenvi, A.B., Kettner, C.A., and Agard, D.A. (1987). Serine protease mechanism: structure of an inhibitory complex of alpha-lytic protease and a tightly bound peptide boronic acid. Biochemistry 26, 7609-7614.
4. Chan, J.M., Stampfer, M.J., Giovannucci, E., Gann, P.H., Ma, J., Wilkinson, P., Hennekens, C.H., and Pollak, M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566. (Pubitemid 28067285)
5. Cohen, P., Graves, H.C., Peehl, D.M., Kamarei, M., Giudice, L.C., and Rosenfeld, R.G. (1992). Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75, 1046-1053.
6. Coombs, G.S., Bergstrom, R.C., Pellequer, J.L., Baker, S.I., Navre, M., Smith, M.M., Tainer, J.A., Madison, E.L., and Corey, D.R. (1998). Substrate specificity of prostate-specific antigen. Chem. Biol. 5, 475-488.
7. Cramer, S.D., Chen, Z., and Peehl, D.M. (1996). Prostate specific antigen cleaves parathyroid hormone-related protein in the PTHlike domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 15, 526-531.
8. Crawford, E.D., Eisenberger, M.A., McLeod, D.G., Spaulding, J.T., Benson, R., Dorr, F.A., Blumenstein, B.A., Davis, M.A., and Goodman, P.J. (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321, 419-424.
9. Culig, Z., Hobisch, A., Cronauer, M.V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., Klocker, H. (1995). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Eur. Urol. 27 (Suppl.), 45-47.
10. Dallas, S.L., Zhao, S., Cramer, S.D., Chen, Z., Peehl, D.M., and Bonewald, L.F. (2005). Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J. Cell. Physiol. 202, 361-370.
11. Debela, M., Magdolen, V., Schechter, N., Valachova, M., Lottspeich, F., Craik, C.S., Choe, Y., Bode, W., and Goettig, P. (2006). Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 281, 25678-25688.
12. Denmeade, S.R. and Isaacs, J.T. (2004). The role of prostate-specific antigen in the clinical evaluation of prostate cancer. BJU Int. 1 (Suppl.), 10-15.
13. Denmeade, S.R., Lou, W., Malm, J., Lovgren, J., Lilja, H., and Isaacs, J.T. (1997). Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res. 57, 4924-4930.
14. Denmeade, S.R., Nagy, A., Gao, J., Lilja, H., Schally, A., and Isaacs, J.T. (1998). Enzymatic-activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 58, 2537-2540.
15. Denmeade, S.R., Jakobsen, C., Janssen, S., Khan, S.R., Lilja, H., Christensen, S.B., and Isaacs, J.T. (2003). Prostate-specific antigen (PSA) activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl. Cancer Inst. 95, 990-1000.
16. Fortier, A.H., Nelson, B.J., Grella, D.K., and Holaday, J.W. (1999). Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 91, 1635-1640.
17. Fortier, A.H., Holaday, J.W., Liang, H., Dey, C., Grella, D.K., Holland-Linn, J., Vu, H., Plum, S.M., and Nelson, B.J. (2003). Recombinant prostate-specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56, 212-219.
18. Grande, M., Carlströ K., Lundh Rozell, B., Stege, R., and Pousette, Å (2000). Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients. Clin. Cancer Res. 6, 1790-1795.
19. Green, B.G., Chabin, R., Mills, S., Underwood, D.J., Shah, S.K., Kuo, D., Gale, P., Maycock, A.L., Liesch, J., Burgey, C.S., et al. (1995). Mechanism of inhibition of human leucocyte elastase by beta-lactams. Stability, reactivation kinetics, and products of beta-lactam-derived E-I complexes. Biochemistry 44, 14331-14343.
20. Gygi, C.M., Leibovitch, I.Y., Adlington, R., Baldwin, J.E., Chen, B., McCoull, W., Pritchard, G.J., Becker, G.W., Dixon, E.P., Little, S.P., et al. (2002). Prostate-specific antigen (PSA)-mediated proliferation, androgenic regulation and inhibitory effects of LY312340 in HOS-TE85 (TE85) human osteosarcoma cells. Anticancer Res. 5, 2725-2732.
21. Huang, A., Knoell, C., Fey, G., Hazegh-Azam, M., Tashjian, A., Hedstrom, L., and Abeles, R.H. (2001). Modulation of recombinant human prostate-specific antigen: activation by hofmeister salts and inhibition by azapeptides. Biochemistry 40, 11734-11741.
22. Iwamura, M., Sluss, P.M., Casamento, J.B., and Cockett, A.T. (1993). Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22, 243-252. (Pubitemid 23184735)
23. Iwamura, M., Hellman, J., Cockett, A.T., Lilja, H., and Gershagen, S. (1996). Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48, 317-325.
24. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. (2007). Cancer statistics. CA Cancer J. Clin. 57, 43-66.
25. Kanety, H., Madjar, Y., Dagan, Y., Levi, J., Papa, M.Z., Pariente, C., Goldwasser, B., and Karasik, A. (1993). Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. 77, 229-233.
26. Knight, W.B., Green, B.G., Chabin, R.M., Gale, P., Maycock, A.L., Weston, H., Kuo, D.W., Westler, W.M., Dorn, C.P., and Finke, P.E. (1992). Specificity, stability, and potency of monocyclic blactam inhibitors of human leukocyte elastase. Biochemistry 35, 8160-8170.
27. Koistinen, H., Paju, A., Koistinen, R., Finne, P., Lögren, J., Wu, P., Seppää M., and Stenman, U.H. (2002). Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50, 112-118.
28. Koistinen, H., Näväen, A., Pakkala, M., Hekim, C., Mattsson, J.M., Laakkonen, P., and Stenman, U.H. (2008a). Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol. Chem. 389, 633-642.
29. Koistinen, H., Wohlfart, G., Mattsson, J.M., Wu, P., Lahdenpera, J., and Stenman, U.H. (2008b). Novel small molecule inhibitors for prostate-specific antigen. Prostate 68, 1143-1151.
30. Kurkela, R., Herrala, A., Hennu, P., Nal, H., and Vihko, P. (1995). Expression of active, secreted human prostate-specific antigen by recombinant baculovirus-infected insect cells on a pilot scale. Biotechnology 13, 1230-1234.
31. Laufer, M., Denmeade, S.R., Sinibaldi, V.J., Carducci, M.A., and Eisenberger, M.A. (2000) Complete androgen blockade for prostate cancer: what went wrong? J. Urol. 164, 3-9.
32. Lawrence, D.A. (2001). Latent-TGF-b: an overview. Mol. Cell. Biochem. 219, 163-170.
33. LeBeau, A.M., Singh, P., Isaacs, J.T., and Denmeade, S.R. (2008). Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem. Biol. 15, 665-674.
34. LeBeau, A.M., Singh, P., Isaacs, J.T., and Denmeade, S.R. (2009a). Prostate-specific antigen is a 'chymotrypsin-like' serine protease with unique P1 substrate specificity. Biochemistry 15, 3490-3496.
35. LeBeau, A.M., Banerjee, S.R., Pomper, M.G., Mease, R.C., and Denmeade, S.R. (2009b). Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorg. Med. Chem. 17, 4888-4893.
36. Lilja, H. (1985). A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899-1903.
37. Lilja, H., Abrahamsson, P.-A., and Lundwall, A. (1989). Semenogelin, the predominant protein in human semen. J. Biol. Chem. 264, 1894-1900.
38. Lilja, H., Piironen, T.P., Rittenhouse, H.G., Mikolajczyk, S.D., and Slawin, K.M. (2000). Prostate-specific antigen. In: Comprehensive Textbook of Genitourinary Oncology, N.J. Vogelzang, W.U. Shipley, P.T. Scardino and D.S. Coffey, eds. (Philadelphia, PA, USA: Lippincott Williams and Wilkins), pp. 638-650.
39. Malm, J., Hellman, J., Hogg, P., and Lilja, H. (2000). Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn2q, a tight-binding inhibitor. Prostate 45, 132-139.
40. Mattsson, J.M., Laakkonen, P., Stenman, U.H., and Koistinen, H. (2009). Antiangiogenic properties of prostate-specific antigen. Scand. J. Clin. Lab. Invest. 69, 447-451.
41. Menez, R., Michel, S., Muller, B.H., Bossus, M., Ducancel, F., Jolivet-Reynaud, C., and Stura, E.A. (2008). Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody. J. Mol. Biol. 376, 1021-1033.
42. Nadiminty, N., Lou, W., Lee, S.O., Mehraein-Ghomi, F., Kirk, J.S., Conroy, J.M., Zhang, H., and Gao, A.C. (2006). Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin. Cancer Res. 12, 1420-1430.
43. O'Keefe, R.J. and Guise, T.A. (2003). Molecular mechanisms of bone metastasis and therapeutic implications. Clin. Orthop. Relat. Res. 415, S100-S104.
44. Romanov, V.I., Whyard, T., Adler, H.L., Waltzer, W.C., and Zucker, S. (2004). Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen. Cancer Res. 64, 2083-2089.
45. Roodman, G.D. (2004). Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664.
46. Roudier, M.P., True, L.D., Higano, C.S., Vesselle, H., Ellis, W., Lange, P., and Vessella, R.L. (2003). Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol. 34, 646-653.
47. Sarker, D., Reid, A.H., Yap, T.A., and de Bono, J.S. (2009). Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 15, 4799-4805.
48. Singh, P., Williams, S.A., Shah, M.H., Lectka, T., Pritchard, G.J., Isaacs, J.T., and Denmeade, S.R. (2008). Mechanistic insights into the inhibition of prostate specific antigen by b-lactam class compounds. Proteins 77, 984-993.
49. Singh, P., LeBeau, A.M., Lilja, H., Denmeade, S.R., and Isaacs, J.T. (2009). Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins 4, 984-993.
50. Stattin, P., Stenman, U.H., Riboli, E., Hallmans, G., and Kaaks, R. (2001). Ratios of IGF-I, IGF binding protein-3, and prostatespecific antigen in prostate cancer detection. J. Clin. Endocrinol. Metab. 86, 5745-5748.
51. Stege, R., Grande, M., Carlströ K., Tribukait, B., and Pousette, Å (2000). Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin. Cancer Res. 6, 160-165.
52. Vis, A.N. and Schröer, F.H. (2009). Key targets of hormonal treatment of prostate cacner. Part 2: the androgen receptor and 5-a reductase. BJU Int. 104, 1191-1197.
53. Watt, K.W.K., Lee, P.J., M'Timkulu, T., Chan, W.P., and Loor, R. (1986). Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA 83, 3166-3170.
54. Webber, M.M., Waghray, A., and Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1, 1089-1094.
55. Williams, S.A., Singh, P., Isaacs, J.T., and Denmeade, S.R. (2007a). Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67, 312-329.
56. Williams, S.A., Merchant, R.F., Garrett-Mayer, E., Isaacs, J.T., Buckley, J.T., and Denmeade, S.R. (2007b). A prostate-specific antigen-activated channel forming toxin as therapy for prostatic disease. J. Natl. Cancer Inst. 99, 376-385.
57. Wong, B.K., DeFeo-Jones, D., Jones, R.E., Garsky, V.M., Feng, D.M., Oliff, A., Chiba, M., Ellis, J.D., and Lin, J.H. (2001). PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab. Dispos. 29, 313-318.
58. Wu, P., Leinonen, J., Koivunen, E., Lankinen, H., and Stenman, U.H. (2000). Identification of novel prostate-specific antigenbinding peptides modulating its enzyme activity. Eur. J. Biochem. 267, 6212-6220.
59. Yang, C.F., Porter, E.S., Boths, J., Kanyi, D., Hsieh, M., and Cooperman, B.S. (1999). Design of synthetic hexapeptide substrates for prostate-specific antigen using single-position minilibraries. J. Pept. Res. 54, 444-448.
60. Yousef, G.M. and Diamandis, E.P. (2003). An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. Clin. Biochem. 36, 443-452.